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Abstract
Previous studies have shown that expression of GLUT4 is decreased in arterial
smooth muscle of hypertensive rats and mice and that total body overexpres-
sion of GLUT4 in mice prevents enhanced arterial reactivity in hypertension.
To demonstrate that the effect of GLUT4 overexpression on vascular responses
is dependent on vascular smooth muscle GLUT4 rather than on some
systemic effect we developed and tested smooth-muscle-specific GLUT4
transgenic mice (SMG4). When made hypertensive with angiotensin II, both
wild-type and SMG4 mice exhibited similarly increased systolic blood pres-
sure. Responsiveness to phenylephrine, serotonin, and prostaglandin F2a was
significantly increased in endothelium-intact aortic rings from hypertensive
wild-type mice but not in aortae of SMG4 mice. Inhibition of Rho-kinase
equally reduced serotonin-stimulated contractility in aortae of hypertensive
wild-type and SMG4-mice. In addition, acetylcholine-stimulated relaxation
was significantly decreased in aortic rings of hypertensive wild-type mice,
but not in rings of SMG4 mice. Inhibition of either prostacylin receptors or
cyclooxygenase-2 reduced relaxation in rings of hypertensive SMG4 mice.
Inhibition of cyclooxygenase-2 had no effect on relaxation in rings of hyper-
tensive wild-type mice. Cyclooxygenase-2 protein expression was decreased in
hypertensive wild-type aortae but not in hypertensive SMG4 aortae compared
to nonhypertensive controls. Our results demonstrate that smooth muscle
expression of GLUT4 exerts a major effect on smooth muscle contractile
responses and endothelium-dependent vasorelaxation and that normal expres-
sion of GLUT4 in vascular smooth muscle is required for appropriate smooth
muscle and endothelial responses.
Introduction
The insulin responsive glucose transporter, GLUT4, is
expressed in vascular smooth muscle (VSM) (Brosius
et al. 1992; Marcus et al. 1994; Banz et al. 1996; Bergandi
et al. 2003). We have previously shown that GLUT4
participates in constitutive, noninsulin-dependent glucose
uptake in arterial VSM (Atkins et al. 2001; Park et al.
2005). This unusual property distinguishes VSM from
other tissues that express GLUT4 as in those tissues
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GLUT4 largely resides in intracellular vesicles until trans-
located to the plasma membrane in response to insulin or
other physiologic stimuli (Bryant et al. 2002). In addition,
we have reported that GLUT4 expression is decreased in
large arteries of hypertensive rats and mice (Atkins et al.
2001, 2005; Park et al. 2005) and that, similar to arteries
from hypertensive animals, arterial reactivity in arteries
from GLUT4 knockout mice is increased compared to
vessels from wild-type (WT) animals (Park et al. 2005).
Using whole body GLUT4 overexpressing mice, we dem-
onstrated that the preserved expression of GLUT4 in
DOCA-salt hypertension prevented the enhanced response
to serotonin (5-HT) observed in aortae of hypertensive
WT mice (Atkins et al. 2007). These latter results left
open the possibility that systemic metabolic changes
resulting from whole body GLUT4 overexpression, and
not GLUT4 overexpression specifically in vascular smooth
muscle, were responsible for the salutory effects observed
in vascular reactivity.
To test whether vascular smooth muscle GLUT4
expression prevented the vascular contractile abnormali-
ties in hypertensive vessels, we generated and studied a
mouse model that overexpressed GLUT4 only in smooth
muscle. Here, we report that maintenance of vascular
smooth muscle GLUT4 expression prevents development
of enhanced vasoconstrictive responses in hypertension.
Moreover, persistently normal vascular smooth muscle
GLUT4 expression dramatically ameliorated endothelial
dysfunction observed in hypertension. These results con-
firm and extend our previous findings suggesting that loss
of vascular smooth muscle GLUT4 expression leads to
abnormal vasoreactivty in hypertension and implicate
complex mechanisms by which maintenance of vascular
smooth muscle GLUT4 expression can normalize defects
in endothelium-dependent vasorelaxation.
Materials and Methods
Animal models
The smooth-muscle-specific GLUT4 transgene (SMG4)
was constructed using the 3.6 kb mouse smooth muscle
a-actin promoter (SMP8; Wang et al. 1997) ligated
upstream of 7.5 kb of the mouse GLUT4 gene (Tsao et al.
1996). An 850 bp fragment containing the SV40 poly A
site was ligated to the 30 end of the GLUT4 gene for tran-
script stability (Fig. 1). The transgene fragment was puri-
fied following restriction with NotI and electrophoresis on
a 1.0% agarose gel for excision. Standard pronuclear
microinjection into FVB fertilized eggs and implantation
into foster females was completed at the Transgenic
Mouse Facility of the Albert Einstein College of Medicine.
GLUT4 transgenic animals were identified by PCR ampli-
fication of tail DNA using primers 50 GCT ACT GCT
GAC TCT CAA CAT T 30 and 50 GGA CAA ACC ACA
ACT AGA ATG C 30, and 50 TCC TCA AAG ATG CTC
ATT AG 30 and 50 GTA ACT CAC TCA TGC AAA GT 30
which amplify a 600-base pair or a 400-base pair product,
respectively, from SMG4, and WT mice. The SMG4 trans-
gene was backcrossed onto the C57BL/6J background for
>10 generations prior to initiating the experiments
detailed below. Transgene expression was confirmed in
SMG4 mice using total RNA extracted from various tis-
sues using the TRIZOL Reagent (Life Technologies)
according to the manufacturer’s instructions. Approxi-
mately 8 lg of total RNA was loaded onto a 1.2% form-
aldehyde-agarose gel, transferred to a Hybond-N nylon
membrane (Amersham, Piscataway, NJ), then hybridized
overnight to a random primed 32P-labeled poly A probe
under high-stringency conditions (50% formamide,
42°C). The filter was washed at 42°C in 0.2x SSC, 0.1%
SDS solution and subjected to phosphoimage analysis.
Induction of hypertension
Adult male mice (25–30 g) were anesthetized with isoflu-
orane and a 14-day osmotic mini-pump (Durect, Cuper-
tino, CA) containing vehicle or AngII (Phoenix
Pharmaceuticals, Burlingame, CA) to deliver at the rate of
1.4 mg/kg/d was placed subcutaneously in the mid-scapu-
lar region. Systolic blood pressure in conscious mice was
measured by the tail-cuff method (CODA, Kent Scientific,
Torrington, CT) after 2 weeks of AngII infusion. Mice
were then anesthetized with pentobarbital (50 mg/kg i.p.)
and both muscles of the diaphragms were cut. The tho-
racic aorta (from aortic arch to diaphragm) from each
animal was removed, carefully cleaned and either used for
reactivity or snap frozen in liquid nitrogen and stored at
80°C. The procedures used in this study were approved
by the University of Michigan Committee on the Use and
Care of Animals and the Albert Einstein College of Medi-
cine Institutional Animal Care and Use Committee. The
University of Michigan Unit for Laboratory Animal Medi-
cine provided veterinary care for the animals reported in
this study. Both the University of Michigan and Albert
Einstein College of Medicine are accredited by the Ameri-
Figure 1. Schematic of the smooth muscle GLUT4 (SMG4)
transgene. The 3.6 kb mouse SMP8 promoter was cloned upstream
of the mouse GLUT4 coding sequences followed by a 850-bp SV40
poly A tail.
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can Association of Laboratory Animal Care. The animal
care and use programs conform to the standards in “The
Guide for the Care and Use of Laboratory Animals,”
Department of Health, Education, and Welfare Publica-
tion No. 86-23.
Immunoblotting
Frozen vascular samples were pulverized by bead-
homgenization (TissueLyser, Qiagen, Germantown, MD),
suspended in the presence of sodium dodecyl sulfate
(SDS)-polyacrylamide gel electrophoresis (PAGE) loading
buffer (125 mmol/l Tris-HCl, pH 6.8, 4% SDS, 20% glyc-
erol, 100 mmol/l PMSF, 10 mg/mL aprotinin, 1 mg/mL
leupeptin, 1 mg/mL pepstatin A), and sonicated, as previ-
ously reported (Atkins et al. 2005, 2007; Park et al. 2005).
Protein concentration was determined (Pierce BCA,
Thermo, Rockford, IL) and lysates (50 lg) were run on
7.5 or 10% SDS-PAGE and immunoblotted with antibod-
ies for GLUT4 (MW~55 kD – Abcam, Cambridge, MA),
pERM (MW~90 kD), pMYPT (MW~130 kD – Thr850),
and COX-2 (MW~72 kD – Santa Cruz Biotechnology,
Santa Cruz, CA), and MYPT (MW~130 kD – BD Bio-
sciences, San Jose, CA). All blots were within the linear
range and, with the exception of those for pMYPT (nor-
malized to total MYPT), were normalized to SM a-actin
(MW~41 kD) or a-actinin (MW~100 kD – Sigma, St
Louis, MO) the expression of which we have found are
unaffected by hypertension (Armoni et al. 2014). Immu-
noblots for GLUT4 exhibit multiple bands due to the
highly glycosylated nature of this protein (Brosius et al.
1992; Katz et al. 1995; Atkins et al. 2001, 2005, 2007;
Park et al. 2005).
Vascular reactivity experiments
These experiments were performed as previously detailed
(Marchesi et al. 2013). Briefly, mouse aortae were cleaned
and cut into 3-mm length rings. The aortic rings were
mounted in a myograph system (Danish Myo Technology
A/S, Aarhus, Denmark). Vessels were bathed with warmed
(37°C), aerated (95% O2/5% CO2) physiological salt solu-
tion (PSS, mmol/L: NaCl 130, KCl 4.7, KHPO4 1.18,
MgSO4 1.17, CaCl2 1.6, NaHCO3 14.9, dextrose 5.5,
CaNa2 EDTA 0.03). Rings were set at 700 mg passive ten-
sion and equilibrated for 1 h, washing every 20 min.
Prior to performing concentration–response curves, ves-
sels were contracted with isotonic PSS containing
60 mmol/L KCl in which an equimolar quantity of KCl
was substituted for NaCl (KPSS) for 10 min. After wash-
ing out the 60 mmol/L KPSS, the vessels were contracted
with 100 mmol/L KPSS, allowed to plateau, which was
followed by washout. Cumulative concentrations of phen-
ylephrine (PE), serotonin (5-HT), and prostaglandin F2a
(PGF2a) (Sigma Chemical, St. Louis, MO) were added to
the bath to establish a concentration–response contraction
curve. Contractions were expressed as a percent of the
100 mmol/L KPSS contraction. Rings were contracted
with a concentration of PE equal to that which stimulated
80% of the maximum force generated in the cumulative
curve. After allowing the contraction to plateau, cumula-
tive concentrations of acetylcholine (Ach) were added to
establish a concentration–response relaxation curve. Rings
similarly contracted to PE were also treated with cumula-
tive concentrations of sodium nitroprusside (SNP). In
both instances, Ach and SNP (Sigma Chemical, St. Louis,
MO), the force is expressed as a percent of that achieved
with 80% PE. In all cases where the effect of inhibition
(Y-27632, CAY10404, CAY10441; Cayman Chemical, Ann
Arbor, MI) was tested separate rings from the same aorta
were treated with or without the inhibitor. Inhibitor was
added 30 min. prior to agonist treatment.
Statistical evaluation
Data were expressed as means  SEM. Unpaired two-tailed
Student’s t-tests were used to compare results from two
groups. For the vascular reactivity experiments, agonist
EC50 values were calculated with a nonlinear regression
analysis with the algorithm [effect = maximum response/
1 + (EC50/agonist concentration)] using GraphPad Prism
(San Diego, CA). For all other comparisons ANOVA with
Bonferroni post-hoc analysis was performed. Differences
were considered to be statistically significant when
P < 0.05.
Results
SMG4 mice were generated as described in the Materials
and Methods (Fig. 1). Using RNA from a large panel of
tissues, only aorta, bladder, and stomach expressed the
SMG4 transgene (Fig. 2). In contrast to the whole body
GLUT4-transgenic mice we studied previously (Atkins
et al. 2007), the SMG4 transgene was not expressed in
major GLUT4-expressing, insulin responsive tissues (adi-
pose tissue, heart, skeletal muscle; Fig. 2). Systolic blood
pressure significantly increased following 2 weeks of AngII
treatment in both WT and SMG4 mice compared to the
respective Sham-treated mice. There was no difference in
systolic blood pressure between the two AngII-treated
groups (Fig. 3).
As previously reported in several rodent models of
hypertension (Atkins et al. 2001, 2005, 2007; Park et al.
2005), immunoblots demonstrated that GLUT4 expres-
sion was significantly decreased in aortae of WT-Ang II-
treated animals (Fig. 4). GLUT4 levels were significantly
ª 2015 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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higher in aortae of SMG4-Sham mice than in aortae of
WT-Sham mice, and were not significantly decreased in
aortae of SMG4-Ang II mice compared to SMG4-Sham
mice.
In whole body GLUT4-transgenic mice we previously
observed differential aortic expression of phosphorylated
myosin phosphatase targeting subunit (pMYPT) com-
pared to aortae of WT mice (Atkins et al. 2007). Here,
phosphorylation of MYPT was not significantly different
in aortae of SMG4 compared to WT mice, however,
pMYPT was significantly increased in aortae of WT-
AngII-treated mice compared to WT-Sham, SMG4-Sham,
and SMG4 AngII mice (Fig. 5A). Similar results were
observed for phosphorylation of ERM (Ezrin, Radixin,
Moesin; Fig. 5B) as well as for levels of O-GlcNAcylation
of aorta proteins (Fig. 5C). However, pERM levels in aor-
tae of SMG4-Sham mice were significantly lower than
those in WT-Sham mice (Fig. 5B).
Next we assessed maximal vascular contractile response.
The maximal contractile response to three agonists
(5-HT, PE and PGF2a) was significantly greater in aortae
of WT-AngII mice compared to all other groups (Fig. 6A–C).
Furthermore, there was an increase in potency (EC50) with
5-HT and PGF2a but not with PE in aortae from WT-
AngII compared to SMG4-AngII mice (Table 1). Thus,
AngII increased the maximal contractile response to all
three agonists in WT but not SMG4 aortae. AngII also
increased the contractile potency of two of the agonists
(5-HT and PGF2a) in WT but not in SMG4 aortae
(Table 1).
Given that expression of markers of enhanced Rho-
kinase activity (Fig. 5A–C.) were unchanged in aortae of
SMG4-AngII mice, we explored whether modulation of
ROCK accounted for effects of GLUT4 expression on vas-
cular contractility. Using 5-HT, because of the demon-
strated difference in both maximum response and
sensitivity with AngII, we compared responsiveness in
aortae from WT-AngII and SMG4-AngII mice at two
concentrations of the Rho-kinase inhibitor, Y-27632
(Fig. 7; Table 2). The extent of inhibition (percentage of
control Emax) elicited by both concentrations of Y-27632
was similar in WT-AngII and SMG4-AngII (41.6% vs.
38.3% and 73.9% vs. 72.5% at 1 lmol/L and 10 lmol/L,
respectively) aortae (Fig. 7; Table 2).
Maximum responsiveness and potency to acetylcholine-
stimulated relaxation was unchanged in SMG4-Sham
compared to that in WT-Sham aortae (Fig. 8A; Table 3).
Acetylcholine-stimulated maximum relaxation and sensi-
tivity were significantly decreased in WT-AngII aortae
(Fig. 8A; Table 3). In contrast, maximum relaxation and
sensitivity to acetylcholine in SMG4-AngII aortae was not
statistically different. Maximum responsiveness, but not
sensitivity, to acetylcholine was significantly increased in
WT-AngII compared to SMG4-AngII aortae (Fig. 8A;
Table 3). Sodium nitroprusside stimulated relaxation was
similar in aortae from all groups (Fig 8B).
Given evidence suggesting a pathogenic role for COX-2
in endothelial dysfunction (Wang et al. 1997; Seko et al.
2003; Cannon and Cannon 2012; Virdis et al. 2013; Wong
et al. 2013) we investigated the possibility that the effect
of maintenance of GLUT4 expression on endothelial
function might be via inhibition of COX-2. Interestingly,
we found that COX-2 expression was significantly
reduced in aortae from WT-AngII but not SMG4-AngII
mice (Fig. 9). We therefore explored the functional role
of COX-2 in the differential responsiveness to acetylcho-
line noted above. Treatment with the specific COX-2
inhibitor, CAY10404 (1 lmol/L), had no effect on the
relaxation observed in WT-AngII aortae (Fig. 10A). In
contrast, CAY10404 evoked a significant reduction in ace-
tylcholine-stimulated relaxation in SMG4-AngII aortae
Figure 2. Tissue distribution of GLUT4 transgene mRNA
expression. Northern blotting with a Poly A-specific probe showed
that transgene expression was limited to smooth muscle and was
absent from traditionally high GLUT4 expressing tissues such as
heart, skeletal muscle, and adipose tissue (n = 5).
Figure 3. Effect of Angiotensin II (AngII) treatment on systolic
blood pressure in wild-type (WT) and GLUT4 transgenic (SMG4)
mice. Blood pressure was taken by tail-cuff at the end of 2 weeks.
These data represent greater than ≥3 separate trials with n = 5/
group.
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(Fig. 10A). This result indicated a vasodilatory product of
COX-2 action, such as prostacyclin, might be responsible
for the difference in relaxation observed between WT-
AngII and SMG4-AngII aortae. We therefore evaluated
the effect of an inhibitor of the prostacyclin activated IP-
receptor, CAY10441 (5 lmol/L), on Ach-stimulated relax-
ation of aortae. Indeed IP-receptor signaling blockade
inhibited the Ach-stimulated relaxation of SMG4-AngII
aortae (Fig. 10B). The final acetylcholine-stimulated
(Emax) relaxation was not significantly different in aortae
from SMG4-AngII mice treated either with CAY10404
(COX-2 inhibitor) or CAY10441 (IP-receptor blocker)
compared to that observed in aortae of WT-AngII mice
(Fig. 10A and B). Interestingly, relaxation of WT-AngII
aortae was significantly increased by CAY10441 treatment
(Fig. 10B).
Discussion
We have previously demonstrated that arterial smooth
muscle expression of GLUT4 is reduced in several rodent
models of hypertension (Atkins et al. 2001, 2005, 2007;
Park et al. 2005). These models also show enhanced arte-
rial sensitivity to agonists such as 5-HT and ergonovine.
Whether there is a causal connection between reduced
GLUT4 expression and functional vascular abnormalities
seen in hypertension remained to be tested. We previ-
ously demonstrated that increased total force generation,
as well as enhanced sensitivity to agonist stimulation,
occurred in arteries of normotensive GLUT4 null mice
(Park et al. 2005). In addition, transgenic overexpression
of GLUT4 in all GLUT4-expressing tissues prevented the
hypertension-enhanced vascular reactivity seen in several
rodent models of hypertension, despite failing to reduce
blood pressure (Atkins et al. 2007). While these studies
suggested a direct effect of vascular smooth muscle
GLUT4 on vascular reactivity, they did not rule out the
possibility that metabolic changes due to systemic dele-
tion or overexpression of GLUT4 accounted for these
observations. To address this question, we generated a
smooth-muscle-specific GLUT4 transgenic mouse to
determine the direct effect of arterial smooth muscle
GLUT4 expression on vascular reactivity.
As observed with transgenic mice overexpressing
GLUT4 in all GLUT4-expressing tissues, smooth-mus-
cle-specific GLUT4 overexpression had no effect on the
development of hypertension. Conversely, GLUT4 over-
expression in smooth muscle prevented all contractile
abnormalities seen in the hypertensive vessels thereby
confirming a critical role for normal or elevated
GLUT4 in vascular smooth muscle in hypertension. It
is important to emphasize that the effect of increased
GLUT4 expression on vasoreactivity is only observed in
the context of hypertension. There was no apparent
contractile phenotype in the normotensive SMG4 mice
compared to WT, despite the significant differences in
GLUT4 expression. However, whereas GLUT4 expres-
sion decreased in aortae of hypertensive compared
Figure 4. The GLUT4 expression in aortae of Sham- or AngII-treated wild-type or SMG4 mice. The representative GLUT4 immunoblot of aortic
lysates (50 lg) was performed after 2 weeks of treatment and combined data (bar graphs) were derived from ≥3 separate trials (n = 5/group).
Order of lanes of scanned radiographs may have been rearranged to reflect convention of figure and does not alter the information contained
therein.
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AB
C
Figure 5. Expression of targets of Rho-kinase phosphorylation. Myosin targeting subunit Thr850 (A), Ezrin, Radixin, Moesin (ERM; (B) and
O-GlcNac-labeled proteins (C). Immunoblots of aortic lysates (50 lg) were performed after 2 weeks of AngII treatment and combined data
(bar graphs) were derived from ≥3 separate trials (n = 5/group). Order of lanes of scanned radiographs may have been rearranged to reflect
convention of figure and does not alter the information contained therein.
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aortae of normotensive wild-type mice, there was not a
significant decrease in GLUT4 between the two con-
ditions in aortae of SMG4 mice. Significant changes in
vascular responses were only observed between aortae
of normotensive and hypertensive wild-type mice (i.e.,
those aortae in which GLUT4 expression had signifi-
cantly decreased). Thus, the prevention of enhanced
contractility observed in hypertensive SMG4 mice was
likely due to maintaining GLUT4 expression during
hypertension and not an effect of GLUT4 overex-
pression.
The current results and those reported previously
demonstrated that, at least in conduit arteries, there is
an uncoupling of increased reactivity and hypertension.
As we previously reported (Atkins et al. 2007) there was
increased phosphorylation of MYPT, the targeting sub-
unit of myosin phosphatase, in aortae of hypertensive
WT mice. This increase in phospho-MYPT was pre-
vented by specifically overexpressing GLUT4 in the
smooth muscle of these arteries. This targeting subunit,
is a substrate of Rho-kinase (ROCK), and ROCK activa-
tion is associated with increased vasoreactivity in hyper-
tensive rodents (Weber and Webb 2001; Seko et al.
2003; Lee et al. 2004; Hilgers et al. 2007). While it is
believed that the Thr850 residue of MYPT is targeted by
ROCK (Ito et al. 2004; Grassie et al. 2011), in this study
we demonstrated that two other markers of ROCK acti-
vation were also increased in aortae of hypertensive
mice. The phosphorylation of ezrin, radixin, and moesin
(ERM) and acylation with O-linked B-N-acetylglucos-
amine (O-GlcNac) of serine and threonine residues of
cellular proteins were increased in aortae of WT-hyper-
tensive mice. While there was a significant increase in
phospho-ERM in aortae of SMG4-AngII mice compared
to that in SMG4 mice, the former phosphorylation levels
were similar to those in aortae of WT nonhypertensive
mice. As previously demonstrated in DOCA-salt rats
(Lima et al. 2009), O-GlcNAcylation was increased in
angiotensin II hypertensive WT mice and was prevented
by smooth muscle GLUT4 overexpression in hyperten-
sive SMG4 mice. These observations suggest that main-
taining the expression of smooth muscle GLUT4
prevented or significantly limited the activation of
ROCK in hypertensive aortae.
Given the potentially causal role of ROCK activation in
the contractile abnormalities of hypertensive WT mice
and the apparently reduced ROCK activation in hyperten-
sive SMG4 mice, we investigated the possibility that
ROCK might be an intermediary in the mechanism of
GLUT4 effects on contractility. Our findings suggest that
the differences in observed contractility to 5-HT between
WT-AngII and SMG4-AngII aortae were not explained by
changes in ROCK activity as the response to 5-HT at each
concentration of Y-27632 was the same in aortae of
WT-AngII and SMG4-AngII mice. Thus, the mechanism
of reduced contractility observed in aortae of hypertensive
SMG4 mice was not dependent upon decreased ROCK
activation.
While ROCK activation was not essential, the preven-
tion of increased responsiveness to contractile agonists in
the aortae of hypertensive SMG4 mice nonetheless may
have been due to preserved myosin light chain phospha-
tase activity. Phosphorylation of MYPT leads to reduced
myosin phosphatase activity (Hirano et al. 2003, 2004),
A
B
C
Figure 6. Reactivity to serotonin (5-HT; A), phenylephrine (PE; B),
and prostagandin F2a (PGF2a; C) by endothelium-intact aortic rings
from Sham- or AngII-treated wild-type or SMG4 mice after 2 weeks
of treatment. Concentration–response curves are expressed as a
percentage of the contraction elicited by 100 mmol/L KPSS. Data
were derived from ≥3 separate trials (n = 5/group).
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and increased reactivity by increased calcium sensitiza-
tion resulting from inhibition of dephosphorylation of
myosin light chain by myosin phosphatase (Hirano et al.
2003, 2004; Lee et al. 2004). By whatever mechanism,
maintenance of GLUT4 was associated with suppression
of hypertension-induced increased expression of pMYPT
(Atkins et al. 2007). Moreover, reduced GLUT4 levels
and increased pMYPT led to an enhanced response to
contractile agonists (Park et al. 2005; Atkins et al. 2007).
This association is supported by our previous finding
that GLUT4 ablation results in increased MYPT phos-
phorylation and increased contractility in normotensive
GLUT4 knockout mice (Park et al. 2005). These latter
observations demonstrated functional effects of GLUT4
Table 1. Potency of 5-HT, PE, and PGF2a in thoracic aorta of WT or SMG4 mice with or without angiotensin II (AngII).
logEC50
5-HT PE PGF2a
WT-SHAM 7.661  0.065* 7.279  0.113 5.949  0.087#
WT-Angll 7.273  0.102 7.534  0.057 5.524  0.044**
SMG4-SHAM 7.721  0.111* 7.411  0.073 5.607  0.096
SMG4-Angll 7.336  0.071* 7.473  0.077 5.567  0.057**
Values are mean  SE; n ≥ 15. *P < 0.001 versus WT-AngII; **P < 0.01 versus WT-SHAM; #P < 0.05 versus SMG4-SHAM; by one-way ANO-
VA with Bonferroni multiple comparisons post hoc test.
Figure 7. Effect of inhibition of Rho-kinase on 5-HT stimulated
contractility of endothelium-intact aortic rings of wild-type and
SMG4 mice after 2 weeks of AngII treatment. Concentration–
response curves are expressed as a percentage of the contraction
elicited by 100 mmol/L KPSS. Data were derived from ≥3 separate
trials (n = 5/group).
Table 2. Potency of 5-HT with or without inhibition of Rho-kinase
by Y-27632 in thoracic aorta of WT or SMG4 mice treated with
angiotensin II (AngII).
Emax_5-HT
WT-AngII SMG4-AngII
Control 162.3  8.27 122.4  3.38
1 µmol/L Y-27632 94.78  5.17 75.56  3.73
10 µmol/L Y-27632 42.32  1.42 33.66  1.71
Values are mean  SE; n ≥ 15.
A
B
Figure 8. Acetylcholine- (A) or sodium nitroprusside-stimulated (B)
relaxation in aortic rings of Sham- or AngII-treated wild-type or
SMG4 after 2 weeks of treatment. Force is expressed as a percent
of that achieved with 80% PE (see methods). Data were derived
from ≥3 separate trials (n = 5/group).
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on vascular responsiveness even in the absence of under-
lying cardiovascular pathology.
Interestingly, this study found that maintenance of
GLUT4 expression in vascular smooth muscle prevented
the development of endothelial dysfunction (reduced
endothelium-dependent relaxation to acetylcholine) typi-
cally exhibited by aortae of WT-hypertensive mice. The
somewhat surprising observation that a protein expressed
exclusively in smooth muscle can regulate endothelial
responsiveness has precedence in previously published
results that demonstrated impaired endothelium-depen-
dent relaxation in tissue-specific knockout of the vascular
smooth muscle PPARc (Marchesi et al. 2013).
Our data suggest that the mechanism by which GLUT4
modulated endothelial function in hypertensive SMG4
aortae was via COX-2 activation. Inhibition of COX-2, as
well as inhibition of IP-receptors, in aortae of hyperten-
sive SMG4 mice reduced endothelium-dependent relaxa-
tion to the level found in aortae from hypertensive WT
mice. These results suggest that decreased relaxation in
aortae of hypertensive WT mice, due to decreased
expression of GLUT4, was mediated by reduced COX-2-
dependent prostacyclin production. In support of this
hypothesis, immunoblots demonstrated a reduction in
COX-2 expression in aortae of hypertensive WT mice
compared to that in aortae of hypertensive SMG4 mice.
Vascular-specific COX-2 deletion has been shown to
result in endothelial dysfunction (Yu et al. 2012). More-
over, prostacyclin biosynthesis was suppressed by vascular
smooth-muscle-specific deletion of COX-2 (Yu et al.
2012). Our finding that relaxation in aortae of hyperten-
sive WT mice was enhanced by IP-receptor blockade was
opposite what we anticipated. The concentration of the
IP-receptor (blocker) used in these experiments also
inhibited U46619-mediated vasoconstriction (not shown)
suggesting dual blockade of IP and TP (thromboxane A2)
receptors by this inhibitor. Thus, elevated thromboxane
A2 activity may be present in the aortae of hypertensive
WT mice which has been shown to be involved in
decreased acetylcholine-dependent relaxation (Wong and
Vanhoutte 2010). It is also possible that there was an
excess production of prostacyclin in the hypertensive WT
mice aortae as it has been demonstrated that in some
vascular pathologic conditions excess prostacyclin pro-
duction leads to activation of TP receptors (Wong and
Vanhoutte 2010), although we did not observe the endo-
thelium-dependent contractions associated with this phe-
nomena.
Table 3. Potency of Ach in thoracic aorta of WT or SMG4 mice
treated with or without angiotensin II (AngII).
logEC50Ach
WT-SHAM 7.459  0.119
WT-Angll 6.702  0.168*
SMG4-SHAM 7.446  0.102
SMG4-Angll 7.006  0.102
Values are mean  SE; n ≥ 15. *P < 0.01 versus WT-Sham,
SMG4-SHAM by one-way ANOVA with Bonferroni multiple com-
parisons post hoc test.
Figure 9. The COX-2 expression in aortae of Sham- or AngII-treated wild-type or SMG4 mice. The representative GLUT4 immunoblot of aortic
lysates (50 lg) was performed after 2 weeks of treatment and combined data (bar graphs) were derived from ≥3 separate trials (n = 5/group).
Order of lanes of scanned radiographs may have been rearranged to reflect convention of figure and does not alter the information contained
therein.
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In summary, we have shown that maintenance of
GLUT4 expression in aortae of mice, which is decreased
with hypertension, was sufficient to block hypertension-
induced increased arterial contractility and decreased
arterial relaxation. It is probable that the effect of GLUT4
on contractility was associated was mediated by the phos-
phorylation status of MYPT. However, the most interest-
ing finding was that maintenance of vascular smooth
muscle GLUT4 expression exerted profound effects on
endothelial function. The mechanism for this effect
appeared to involve COX-2 activity and prostacyclin sig-
naling through IP-receptors. The mechanism whereby
changes in GLUT4 expression modulated MYPT phos-
phorylation, COX-2 activation and downstream produc-
tion of prostacyclin remains to be elucidated.
Limitations
Our previous results (Atkins et al. 2007) and those
reported herein demonstrate that maintaining GLUT4
expression in aortae of hypertensive mice prevents
increased responses to contractile agonists. Our data dem-
onstrate these effects in a conduit vessel, but leaves open
the question of what is the response in resistance vessels.
Our results, both previously (Atkins et al. 2007) and here,
demonstrate that there is no significant blood pressure
difference between hypertensive wild-type and transgenic
mice. This suggests that there is no difference in contrac-
tile agonist-stimulated responses between resistance vessels
of hypertensive wild-type and transgenic mice given the
role of resistance vessels in peripheral resistance and
hypertension (Lund-Johansen 1983; Mulvany 2005). Con-
firmation of this supposition would, however, be of inter-
est in a follow-up study.
The consideration of the lack of blood pressure differ-
ences begs the question of the sensitivity of the tail-cuff
measurement we employed. Measurement of rodent blood
pressure using the VPR method employed herein has
been demonstrated to show good agreement with those
obtained by telemetry (Feng et al. 2008). Whether we
may have missed a small but significant difference in the
elevated level of blood pressure that could explain differ-
ences in response to agonist stimulation is unlikely given
that the actual extent of increase (from normotensive to
hypertensive) in blood pressure observed in the two geno-
types was similar if not actually larger in the transgenic
mice.
We do not know the mechanism by which GLUT4
gene expression affects vascular responses in hypertensive
aortae. We have demonstrated that COX-2 is involved in
this mechanism, but do not know how GLUT4 expression
modulates COX-2 activity. While GLUT4 expression also
modulates Rho-kinase activity, this effect does not seem
to be associated with the GLUT4-induced changes in vas-
cular responses that we have found.
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